Ieq Capital LLC Buys New Holdings in Ventyx Biosciences, Inc. $VTYX

Key Points

• Ieq Capital LLC acquired 194,189 shares of Ventyx Biosciences, valued at approximately $223,000, representing about 0.27% of the company's stock.
• Ventyx Biosciences' stock is currently trading at $2.52, with a 52-week range between $0.78 and $3.39.
• Analysts have upgraded Ventyx Biosciences from a "sell" to a "hold" rating, with a consensus target price of $7.50.

Ieq Capital LLC bought a new position in Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 194,189 shares of the company's stock, valued at approximately $223,000. Ieq Capital LLC owned about 0.27% of Ventyx Biosciences as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Wealth Enhancement Advisory Services LLC purchased a new position in Ventyx Biosciences in the first quarter worth about $28,000. Cerity Partners LLC purchased a new position in Ventyx Biosciences in the first quarter worth about $56,000. MetLife Investment Management LLC boosted its position in Ventyx Biosciences by 76.0% in the fourth quarter. MetLife Investment Management LLC now owns 26,731 shares of the company's stock worth $59,000 after purchasing an additional 11,543 shares during the last quarter. CWM LLC boosted its position in Ventyx Biosciences by 1,733.8% in the first quarter. CWM LLC now owns 53,088 shares of the company's stock worth $61,000 after purchasing an additional 50,193 shares during the last quarter. Finally, Cutter & CO Brokerage Inc. purchased a new position in Ventyx Biosciences in the first quarter worth about $62,000. 97.88% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised Ventyx Biosciences from a "sell" rating to a "hold" rating in a research report on Saturday, August 9th. One equities research analyst has rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $7.50.

Ventyx Biosciences Price Performance

Shares of VTYX stock traded down $0.04 during trading hours on Friday, reaching $2.35. 66,231 shares of the company traded hands, compared to its average volume of 1,289,980. Ventyx Biosciences, Inc. has a 12-month low of $0.78 and a 12-month high of $3.39. The company has a market cap of $167.22 million, a P/E ratio of -1.40 and a beta of 0.95. The firm has a 50-day moving average price of $2.68 and a 200 day moving average price of $1.94.

Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.07. Sell-side analysts predict that Ventyx Biosciences, Inc. will post -2.09 EPS for the current year.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.